Viatris Dishes On Insulin Aspart Biosimilar As Key Date Passes

Company Won Landmark Interchangeable Insulin Glargine Approval In July

Viatris has provided an update on its biosimilar pipeline, covering assets including insulin glargine, insulin aspart, aflibercept and bevacizumab, as part of its second quarter strategic update.

FDABldg1ExteriorWithCircle_1200x675
Viatris/Biocon's insulin aspart has been approved in the EU • Source: Shutterstock

Viatris Inc. says a US Food and Drug Administration pre-approval inspection of partner Biocon’s manufacturing facility in Malaysia in connection with the firms’ NovoLog/NovoRapid (insulin aspart) biosimilar candidate is now scheduled for the end of next month.

Meanwhile, noted president Rajiv Malik, speaking during Viatris’ Q2 earnings call, “we believe we are on track to achieve interchangeability...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.